Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Image 2-Gavreto (pralsetinib)
Gavreto is a RET-targeted, once-daily oral therapy developed by Blueprint Medicines. Credit: Roche.